Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Bortezomib in Relapsed/Refractory Lymphoma
NCT02613598Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 5 Years. Started May 2016; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02613598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613598.